Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04423991 · ClinicalTrials.gov registry record · NA

Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning

A NA study of COVID-19 and Coronavirus, sponsored by Dascena.

Completed
Registry status
NA
Development phase
290
Enrollment target
1
Study location

NCT04423991: Completed NA study of COVID-19 and Coronavirus, sponsored by Dascena.

NCT04423991 is a NA study of COVID-19 and Coronavirus that has completed, run by Dascena. The registered enrollment target is 290 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04423991, a NA study of COVID-19 and Coronavirus, has completed, sponsored by Dascena.

COMPLETED
Registry status
NA
Development phase
290 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study was to assess the performance of a machine learning algorithm which identifies patients for whom hydroxychloroquine treatment is associated with predicted survival.

Primary Outcome

Time to in-hospital death

Interventions

  • DEVICE COViage

Study Locations (1)

California

  • Dascena - Oakland

Trial Details

FieldValue
Enrollment Target 290 participants
Start Date 2020-03-10
Est. Completion 2020-06-04
Phase NA
Dascena

6 total trials

What the finished NCT04423991 record still lists

NCT04423991 is an interventional study that assigns participants to a tested intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which COViage is the first listed.

NCT04423991 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04423991 about?

NCT04423991 is a clinical study titled "Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning". The purpose of this study was to assess the performance of a machine learning algorithm which identifies patients for whom hydroxychloroquine treatment is associated with predicted survival.

What is the current status of trial NCT04423991?

This trial is currently completed. It is a NA study. The enrollment target is 290 participants. The study started on 2020-03-10. Estimated completion is 2020-06-04.

What conditions does trial NCT04423991 study?

This clinical trial studies the following conditions: COVID-19, Coronavirus, Mortality.

What interventions are being tested in trial NCT04423991?

The interventions under investigation include: COViage (DEVICE).

Who is sponsoring clinical trial NCT04423991?

This trial is sponsored by Dascena, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04423991 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04423991's enrollment target sits among peer trials

290 144th of 298 higher than 155 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00775476 · 290 participants · Phase 2

    Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

  • NCT01874197 · 290 participants · NA

    Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic

  • NCT04331353 · 290 participants · NA

    The Allergen Reduction and Child Health Study (ARCHS)

  • NCT04649008 · 290 participants · Early Phase 1

    Localizing Epileptic Networks Using MRI and iEEG

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04423991, the US trial registry maintained by the National Library of Medicine. NCT04423991 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.